CoChat

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

Open access
Seijas-Amigo, Jose, Mauriz-Montero, Mª José, Suarez-Artime, Pedro, Gayoso-Rey, Mónica, Estany-Gestal, Ana, Casas-Martínez, Antonia, González-Freire, Lara, Rodriguez-Vazquez, Ana, Pérez-Rodriguez, Natalia, Villaverde-Piñeiro, Laura, Castro-Rubinos, Concepción, Espino-Faisán, Esther, Rodríguez-Mañero, Moisés, Cordero, Alberto, González-Juanatey, José R., Investigadores MEMOGAL, Paz-Couce, Adrián, Rodriguez-Penas, Diego, Cardeso-Paredes, Begoña, Seoane-Blanco, Ana, Moure-Gonzalez, María, Soler-Martín, Rita, Margusino-Framiñan, Luis, Suarez-Rodriguez, Ana, Rodriguez-Cobos, Marisol, Rojo-Valdés, Juan, Zarra-Ferro, Irene, Lorenzo-Lorenzo, Karina, Casanova-Martinez, Cristina, Crespo-Diz, Carlos, Dominguez-Guerra, María, González-Pereira, María Elena, Anido-García, María, Tajes-Gonzalez, Iveth Michelle, Mozo-Peñalver, Héctor, Silva-Lopez, Alicia, Rodriguez-Sanchez, Jose Luis, García-Verde, María Jesús · 2023 · American Journal of Cardiovascular Drugs
Cited by 13

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in cognitive function domains, to analyze subgroups by the low-density lipoprotein cholesterol (LDL-C) achieved, and differences between alirocumab and evolocumab. METHODS: This has a multicenter, quasi-experimental design carried out in 12 Spanish hospitals from May 2020 to February 2023. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). RESULTS: Among 158 patients followed for a median of 99 weeks, 52% were taking evolocumab and 48% alirocumab; the mean change from baseline in MoCA score at follow-up was + 0.28 [95% CI (- 0.17 to 0.73; p = 0.216)]. There were no significant differences in the secondary endpoints-the visuospatial/executive domain + 0.04 (p = 0.651), naming domain - 0.01 (p = 0.671), attention/memory domain + 0.01 (p = 0.945); language domain - 0.10 (p = 0.145), abstraction domain + 0.03 (p = 0.624), and orientation domain - 0.05 (p = 0.224)-but for delayed recall memory the mean change was statistically significant (improvement) + 0.44 (p = 0.001). Neither were there any differences in the three stratified subgroups according to lowest attained LDL-C level-0-54 mg/dL, 55-69 mg/dL and ≥ 70 mg/dL; p = 0.454-or between alirocumab and evolocumab arms. CONCLUSION: We did not find effect of monoclonal antibody PCSK9i on neurocognitive function over 24 months of treatment, either in global MoCA score or different cognitive domains. An improvement in delayed recall memory was shown. The study showed no differences in the cognitive function between the prespecified subgroups, even among patients who achieved very low levels of LDL-C. There were no differences between alirocumab and evolocumab. REGISTRATION: ClinicalTtrials.gov Identifier number NCT04319081.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40256-023-00604-6

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 13

Metadata

Authors
Seijas-Amigo, J., Mauriz-Montero, M. J., Suarez-Artime, P., Gayoso-Rey, M., Estany-Gestal, A., Casas-Martínez, A., González-Freire, L., Rodriguez-Vazquez, A., Pérez-Rodriguez, N., Villaverde-Piñeiro, L., Castro-Rubinos, C., Espino-Faisán, E., Rodríguez-Mañero, M., Cordero, A., González-Juanatey, J. R., MEMOGAL, I., Paz-Couce, A., Rodriguez-Penas, D., Cardeso-Paredes, B., Seoane-Blanco, A., Moure-Gonzalez, M., Soler-Martín, R., Margusino-Framiñan, L., Suarez-Rodriguez, A., Rodriguez-Cobos, M., Rojo-Valdés, J., Zarra-Ferro, I., Lorenzo-Lorenzo, K., Casanova-Martinez, C., Crespo-Diz, C., Dominguez-Guerra, M., González-Pereira, M. E., Anido-García, M., Tajes-Gonzalez, I. M., Mozo-Peñalver, H., Silva-Lopez, A., Rodriguez-Sanchez, J. L., & García-Verde, M. J.
Venue
American Journal of Cardiovascular Drugs
Published
2023-08-23
Volume
23
Issue
5
Pages
583-593
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W4386100303
Cited by
13
References
14
FWCI
3.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study. https://app.cochat.ai/papers/10.1007/s40256-023-00604-6
The paper
Seijas-Amigo, J., Mauriz-Montero, M. J., Suarez-Artime, P., Gayoso-Rey, M., Estany-Gestal, A., Casas-Martínez, A., González-Freire, L., Rodriguez-Vazquez, A., Pérez-Rodriguez, N., Villaverde-Piñeiro, L., Castro-Rubinos, C., Espino-Faisán, E., Rodríguez-Mañero, M., Cordero, A., González-Juanatey, J. R., MEMOGAL, I., Paz-Couce, A., Rodriguez-Penas, D., Cardeso-Paredes, B., . . . García-Verde, M. J. (2023). Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-023-00604-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.